PA
NTLA icon

Profund Advisors’s Intellia Therapeutics NTLA Stock Holding History

Profund Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Sell
80,427
-8,628
-10% -$121K 0.04% 282
2026
Q1 		$1.14M Buy
89,055
+9,391
+12% +$120K 0.04% 316
2025
Q4 		$716K Buy
79,664
+40,078
+101% +$552K 0.02% 444
2025
Q3 		$684K Buy
39,586
+12,084
+44% +$149K 0.02% 423
2025
Q2 		$258K Sell
27,502
-10,032
-27% -$82.4K 0.01% 775
2025
Q1 		$267K Sell
37,534
-11,589
-24% -$117K 0.01% 740
2024
Q4 		$573K Sell
49,123
-1,229
-2% -$19.2K 0.02% 444
2024
Q3 		$1.03M Buy
50,352
+11,405
+29% +$263K 0.04% 315
2024
Q2 		$872K Sell
38,947
-9,353
-19% -$223K 0.03% 336
2024
Q1 		$1.33M Sell
48,300
-2,676
-5% -$74.3K 0.05% 277
2023
Q4 		$1.55M Buy
50,976
+10,515
+26% +$302K 0.07% 238
2023
Q3 		$1.28M Buy
40,461
+4,592
+13% +$178K 0.07% 232
2023
Q2 		$1.46M Sell
35,869
-269
-0.7% -$10.9K 0.08% 218
2023
Q1 		$1.35M Buy
36,138
+24,603
+213% +$965K 0.08% 215
2022
Q4 		$402K Buy
11,535
+1,458
+14% +$69.3K 0.03% 497
2022
Q3 		$564K Buy
10,077
+412
+4% +$25.6K 0.04% 356
2022
Q2 		$500K Sell
9,665
-1,021
-10% -$51.8K 0.03% 412
2022
Q1 		$777K Sell
10,686
-1,191
-10% -$101K 0.03% 380
2021
Q4 		$1.4M Sell
11,877
-1,221
-9% -$153K 0.05% 253
2021
Q3 		$1.76M Buy
13,098
+11,222
+598% +$1.7M 0.06% 242
2021
Q2 		$303K Buy
+1,876
New +$146K 0.01% 1054

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Profund Advisors's NTLA Position: Q2 2026 in Review

Profund Advisors reduced its Intellia Therapeutics (NTLA) stake by 9.7% in Q2 2026, selling an estimated $121K and leaving 80,427 shares worth $1.36M. The position accounts for 0.04% of the portfolio, ranked #282.

Profund Advisors first reported a position in NTLA in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.76M in Q3 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Profund Advisors held 80,427 shares of Intellia Therapeutics worth $1.36M as of Q2 2026.
  • Profund Advisors sold 8,628 Intellia Therapeutics shares in Q2 2026, an estimated $121K.
  • Intellia Therapeutics made up 0.04% of Profund Advisors's portfolio in Q2 2026, its #282 holding.
  • Profund Advisors first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Profund Advisors's Intellia Therapeutics position peaked at $1.76M in Q3 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.